Townson Sharon's Form 4 filing
Monte Rosa Therapeutics, Inc. (GLUE) · filed Jan 5, 2026
- Accession no.
- 0001193125-26-002385
- Filed
- Jan 5, 2026
- Trade date
- Jan 2-5, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $47.9K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Townson SharonCIK 0001855689 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Common Stock | AGrant or awardAcquired | +35,000 | – | – | 71,000 | Direct | |
| Jan 5, 2026 | Common Stock | SSaleDisposed | −3,155 | $15.17 | −$47,861.35 | 67,845 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Common Stock | AGrant or awardAcquired | +158,000 | $0.00 | $0 | 158,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.